BLUE:NSD-bluebird bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 55.00

Change

-0.90 (-1.61)%

Market Cap

USD 3.70B

Volume

0.47M

Average Target Price

USD 94.82 (+72.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+2.58 (+0.96%)

USD69.73B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

+1.69 (+0.30%)

USD60.85B 21.61 16.69
SGEN Seattle Genetics, Inc

+0.45 (+0.24%)

USD33.15B N/A N/A
MRNA Moderna, Inc

-0.03 (-0.04%)

USD27.84B N/A N/A
BGNE BeiGene, Ltd

+0.81 (+0.29%)

USD25.12B N/A N/A
RPRX Royalty Pharma plc

+0.80 (+1.94%)

USD25.02B 34.81 9.50
ALXN Alexion Pharmaceuticals, Inc

-0.84 (-0.74%)

USD24.83B 29.87 27.00
GMAB Genmab A/S

+0.38 (+1.03%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

-0.27 (-0.32%)

USD19.77B N/A N/A
INCY Incyte Corporation

-2.93 (-3.24%)

USD19.76B 47.64 35.20

ETFs Containing BLUE

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

-1.42 (-2.35%)

USD0.08B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.32% 24% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.32% 24% F 20% F
Trailing 12 Months  
Capital Gain -36.80% 19% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.80% 19% F 18% F
Trailing 5 Years  
Capital Gain -38.64% 47% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.64% 47% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 27.53% N/A N/A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.53% N/A N/A 83% B
Risk Return Profile  
Volatility (Standard Deviation) 76.96% N/A N/A 13% F
Risk Adjusted Return 35.77% N/A N/A 58% F
Market Capitalization 3.70B 91% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.19 72% C- 49% F
Price / Cash Flow Ratio -6.56 57% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.38% 74% C 28% F
Return on Invested Capital -49.00% 63% D 20% F
Return on Assets -20.36% 68% D+ 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.96 23% F 13% F
Short Percent 13.55% 19% F 16% F
Beta 2.19 19% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector